Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPOCK: Systems Biology Guided Therapy in ER+ Breast Cancer
NCT04965688Phase 2Terminated
- Sponsor
- Inova Health System
- Start
- Aug 2021
- Primary completion
- Mar 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib, fulvestrant, everolimus, exemestane, capecitabine in breast cancer, sponsored by Inova Health System. Started Aug 2021; status: terminated.
02
Drugs
alpelisibfulvestranteverolimusexemestanecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04965688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965688.